Neurology Central

Parkinson’s drug trial authorized by the Medicines Agency of Sweden

The Medicines Agency of Sweden has authorized a Phase I-II clinical study for the investigation of cerebral dopamine neurotrophic factor (CDNF) and Renishaw’s (UK) chronic drug delivery system as a treatment for Parkinson’s disease (PD).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.